Silastic Stent Study
Launched by UNIVERSITY OF BRITISH COLUMBIA · Sep 11, 2017
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients undergoing trans-sphenoidal endoscopic pituitary surgery at their first post-operative appointment
- Exclusion Criteria:
- • patients with inflammatory sinus conditions
- • patients having undergone extensive skull base reconstructions
- • patients having received previous radiotherapy
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Arif Janjua, MD
Principal Investigator
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials